{"id":754353,"date":"2023-05-03T09:48:31","date_gmt":"2023-05-03T13:48:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/"},"modified":"2023-05-03T09:48:31","modified_gmt":"2023-05-03T13:48:31","slug":"cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/","title":{"rendered":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit"},"content":{"rendered":"
\n

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of \u00a33.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represents the amount disclosed in the company\u2019s audited financial statements at December 31, 2022.<\/p>\n

\u201cThe R&D tax credit is an important source of non-dilutive capital. We appreciate the UK government\u2019s support as we develop our novel, oral medicines, fadraciclib and plogosertib, to address unmet medical needs of oncology patients, including patients with women\u2019s cancers and lymphoma,\u201d said Paul McBarron, Executive Vice President, Finance & Chief Operating Officer.<\/p>\n

\n About Cyclacel Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel\u2019s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit\u00a0www.cyclacel.com<\/u><\/a>.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n
Company:<\/td>\nPaul McBarron, (908) 517-7330,\u00a0pmcbarron@cyclacel.com<\/u><\/a><\/td>\n<\/tr>\n
Investor Relations:<\/td>\nGrace Kim, IR@cyclacel.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a9 Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel\u00ae<\/sup> are trademarks of Cyclacel Pharmaceuticals, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of \u00a33.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represents the amount disclosed in the company\u2019s audited financial statements at December 31, 2022. \u201cThe R&D tax credit is an important source of non-dilutive capital. We appreciate the UK government\u2019s support as we develop our novel, oral medicines, fadraciclib and plogosertib, to address unmet … <\/p>\n

Continue reading “Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754353","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of \u00a33.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represents the amount disclosed in the company\u2019s audited financial statements at December 31, 2022. \u201cThe R&D tax credit is an important source of non-dilutive capital. We appreciate the UK government\u2019s support as we develop our novel, oral medicines, fadraciclib and plogosertib, to address unmet … Continue reading "Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-03T13:48:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit\",\"datePublished\":\"2023-05-03T13:48:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/\",\"name\":\"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=\",\"datePublished\":\"2023-05-03T13:48:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/","og_locale":"en_US","og_type":"article","og_title":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of \u00a33.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represents the amount disclosed in the company\u2019s audited financial statements at December 31, 2022. \u201cThe R&D tax credit is an important source of non-dilutive capital. We appreciate the UK government\u2019s support as we develop our novel, oral medicines, fadraciclib and plogosertib, to address unmet … Continue reading \"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-03T13:48:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit","datePublished":"2023-05-03T13:48:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/","name":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=","datePublished":"2023-05-03T13:48:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDk2NyM1NTcyNDEyIzIwMDY3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-announces-receipt-of-4-7-million-rd-tax-credit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754353"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754353\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}